Quantcast

Latest gabapentin Stories

2014-07-17 16:26:16

Opinion Expected "In Short Order" NEWARK, Calif., July 17, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise® (gabapentin) prior to the Court's issuance of an opinion in the matter. The order indicates the Court expects to issue an...

2014-04-21 16:25:13

NEW YORK, April 21, 2014 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) announces a $190 Million settlement, subject to court approval, with Pfizer, Inc. and Warner-Lambert Co. ("Defendants") in In re Neurontin Antitrust Litigation, No. 02-1390, pending in the District of New Jersey. Kaplan Fox serves as one of two co-lead counsel representing a class of direct purchasers of Neurontin from Defendants between December 11, 2002 and August 31, 2008 and who...

2014-04-14 12:33:34

NEWARK, Calif., April 14, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise(®) (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on...

2014-03-10 16:33:25

NEWARK, Calif., March 10, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available...

2014-01-29 08:29:54

NEWARK, Calif., Jan. 29, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today a favorable "Markman" claim construction ruling by Judge Joel A. Pisano of the United States District Court for the District of New Jersey in Depomed's ongoing patent infringement case against filers of three Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of Depomed's GRALISE(®) (gabapentin) product prior to the expiration of Depomed's patents listed for Gralise in...

Neuroscience Study Reveals New Player In Obesity
2014-01-08 08:24:33

Tufts University, Health Sciences Campus A protein directs appetite suppressor in the brain; implications for obesity treatment A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are...

2014-01-06 10:16:35

Gabapentin is a gamma-aminobutyric acid derivative, and was approved for the treatment of neuropathic pain by the U.S. Food and Drug Administration in 2002. However, little evidence is available on the effects and me-chanisms of action of gabapentin during the migraine attack period. A recent study by Yanbo Zhang and colleague from Xuanwu Hospital, Capital Medical University in China showed that excitatory amino acids and protein kinase C are involved in the formation and maintenance of...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related